United States securities and exchange commission logo





                             July 13, 2021

       Todd Harris, Ph.D.
       President and Chief Executive Officer
       Tyra Biosciences, Inc.
       2333 State Street, Suite 201
       Carlsbad, CA 92008

                                                        Re: Tyra Biosciences,
Inc.
                                                            Amendment No. 1 to
Draft Registration Statement on Form S-1
                                                            Submitted July 2,
2021
                                                            CIK No. 0001863127

       Dear Dr. Harris:

              We have reviewed your amended draft registration statement and
have the following
       comment. In our comment, we may ask you to provide us with information
so we may better
       understand your disclosure.

              Please respond to this letter by providing the requested
information and either submitting
       an amended draft registration statement or publicly filing your
registration statement on
       EDGAR. If you do not believe our comment applies to your facts and
circumstances or do not
       believe an amendment is appropriate, please tell us why in your
response.

             After reviewing the information you provide in response to this
comment and your
       amended draft registration statement or filed registration statement, we
may have additional
       comments.

       Amendment No. 1 to Draft Registration Statement Filed on Form S-1

       Risk Factors
       Changes in methods of product candidate manufacturing or formulation may
result in additional
       costs or delay., page 29

   1.                                                   We note your amended
disclosure that you "intend to change the delivery vehicle we use
                                                        in our formulation for
TYRA-300 from polyethylene glycol 400 to a cyclodextrin based
                                                        vehicle" and that
"[t]his change in formulation may result in effects and results that are
                                                        different from those
observed in our completed preclinical studies to date." Please
                                                        provide more
information about this change in a relevant portion of your business section
                                                        and explain whether you
believe your comparisons to erdafitinib and pemigatinib, which
                                                        you previously
addressed in response to comment number 7, are still appropriate.
 Todd Harris, Ph.D.
Tyra Biosciences, Inc.
July 13, 2021
Page 2

        You may contact Kristin Lochhead at 202-551-3664 or Terence O'Brien at
202-551-3355
if you have questions regarding comments on the financial statements and
related matters. Please
contact Dillon Hagius at 202-551-7967 or Chris Edwards at 202-551-6761 with any
other
questions.



                                                           Sincerely,
FirstName LastNameTodd Harris, Ph.D.
                                                           Division of
Corporation Finance
Comapany NameTyra Biosciences, Inc.
                                                           Office of Life
Sciences
July 13, 2021 Page 2
cc:       Matthew T. Bush
FirstName LastName